SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis
1 references·16 citing·44 second hop
Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis (2004)Does NICE have a cost‐effectiveness thres…The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies (1999)The irrelevance of inference:…A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States (2020)A Health Opportunity Cost Thr…Cost-Effectiveness Thresholds: the Past, the Present and the Future (2018)Cost-Effectiveness Thresholds…Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries (2017)Using health technology asses…Attributes and weights in health care priority setting: A systematic review of what counts and to what extent (2015)Attributes and weights in hea…The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions (2014)The Influence of Cost‐Effecti…Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting (2011)Economic evaluation alongside…Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions (2009)Using Effectiveness and Cost-…International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? (2009)International survey on willi…Cost Effectiveness in Low- and Middle-Income Countries (2009)Cost Effectiveness in Low- an…The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004 (2008)The Role of Value for Money i…Priority setting in health care: Lessons from the experiences of eight countries (2008)Priority setting in health ca…Key principles for the improved conduct of health technology assessments for resource allocation decisions (2008)Key principles for the improv…Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)Assessing cost-effectiveness …Competition and Quality: Evidence From the Nhs Internal Market 1991–9 (2007)Competition and Quality: Evid…Assessing the economic challenges posed by orphan drugs (2007)Assessing the economic challe…Bias in published cost effectiveness studies: systematic review (2006)Bias in published cost effect…EuroQol: the current state of play (1996)The estimation of a preference-based measure of health from the SF-36 (2002)Methods for the Economic Evaluation of Health Care Programmes (2005)Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting (2011)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)The Existence of Publication Bias and Risk Factors for Its Occurrence (1990)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Cost-Effectiveness in Health and Medicine (1996)Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2 (2012)Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010 (2014)Corporate practices and health: a framework and mechanisms (2018)A Theory of Justice (1971)Deliberations about deliberative methods: issues in the design and evaluation of public participation processes (2003)Priority setting in health: origins, description and application of the Australian Assessing Cost–Effectiveness initiative (2008)The Economic Analysis of Prevention in Mental Health Programs (2011)‘You’re on the waiting list’: An interpretive phenomenological analysis of young adults’ experiences of waiting lists within mental health services in the UK (2022)Decision Analysis: Introductory Lectures on Choices Under Uncertainty. (1969)Regret Theory: An Alternative Theory of Rational Choice Under Uncertainty (1982)Net Health Benefits (1998)Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. (2008)Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report (2015)Measurement of health state utilities for economic appraisal (1986)The Value of a Statistical Life: A Critical Review of Market Estimates Throughout the World (2003)Cost-Effectiveness of Interventions to Prevent and Control Diabetes Mellitus: A Systematic Review (2010)On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review (2018)Recommendations for Reporting Cost-effectiveness Analyses (1996)Productivity Costs in Economic Evaluations: Past, Present, Future (2013)The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature (2014)Methods for the economic evaluation of health care programmes, 3rd ed (2006)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending (2017)Quasi-Markets and Social Policy (1993)Is Hospital Competition Socially Wasteful? (2000)Handbook of Health Economics (2001)Competition in Health Care Markets (2011)Valuing school quality using boundary discontinuities (2012)Death by Market Power: Reform, Competition, and Patient Outcomes in the National Health Service (2013)A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (2015)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold (2015)Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework (2017)Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward (2019)Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers (2010)
this work references cited by second hop

References

  • 1999The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies891 cited

Cited by

  • 2009International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?692 cited
  • 2008Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold637 cited
  • 2008Key principles for the improved conduct of health technology assessments for resource allocation decisions489 cited
  • 2006Bias in published cost effectiveness studies: systematic review383 cited
  • 2009Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions343 cited
  • 2011Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting319 cited
  • 2007Competition and Quality: Evidence From the Nhs Internal Market 1991–9313 cited
  • 2008Priority setting in health care: Lessons from the experiences of eight countries312 cited
  • 2017Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries306 cited
  • 2007Assessing the economic challenges posed by orphan drugs279 cited
  • 2020A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States242 cited
  • 2014The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

232 cited
  • 2008The Role of Value for Money in Public Insurance Coverage Decisions for Drugs in Australia: A Retrospective Analysis 1994-2004217 cited
  • 2009Cost Effectiveness in Low- and Middle-Income Countries207 cited
  • 2018Cost-Effectiveness Thresholds: the Past, the Present and the Future206 cited
  • 2015Attributes and weights in health care priority setting: A systematic review of what counts and to what extent179 cited